n (% miss.) | No change in PD-L1 score group* (N=55) | Change in PD-L1 score group (N=32) | P value† | |
Summary estimate | Summary estimate | |||
Female gender | 87 (0) | 27 (49%) | 8 (25%) | 0.027 |
Age at diagnosis (years) | 87 (0) | 63 (58–68) | 63 (56–68) | 0.876 |
ECOG performance status | 74 (15) | / | / | 0.900 |
0 points | / | 22 (45%) | 10 (40%) | / |
1 point | / | 23 (47%) | 14 (56%) | / |
≥2 points | / | 4 (8%) | 1 (4%) | / |
Smoking status | 66 (24) | / | / | 0.645 |
Never | / | 4 (10%) | 1 (4%) | / |
Current or former | / | 38 (90%) | 23 (96%) | / |
Histology | 87 (0) | / | / | 0.251 |
Adenocarcinoma | / | 37 (67%) | 16 (50%) | / |
Squamous cell carcinoma | / | 17 (31%) | 15 (47%) | / |
Other | / | 1 (2%) | 1 (3%) | / |
Postoperative tumor stage | 85 (2) | / | / | 0.319 |
I | / | 8 (15%) | 9 (28%) | / |
II | / | 23 (43%) | 13 (41%) | / |
III | / | 22 (42%) | 10 (31%) | / |
Any adjuvant treatment | 87 (0) | 17 (31%) | 12 (38%) | 0.529 |
Time between surgery and rebiopsy ≥1 year | 87 (0) | 37 (67%) | 18 (56%) | 0.304 |
Site of rebiopsy | 87 (0) | / | / | 0.548 |
Local recurrence | / | 26 (47%) | 13 (41%) | / |
Distant recurrence | / | 29 (53%) | 19 (59%) | / |
*PD-L1 score group (PD-L1 negative, PD-L1 low (1%–49%), and PD-L1 high (50%–100%)).
†χ2 test.